NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
4/8 — Partial
Priority Review
TENORMIN (atenolol) by AstraZeneca is clinical pharmacology atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. First approved in 1989.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENORMIN (atenolol) is a beta-1 selective adrenergic receptor blocking agent used to treat hypertension and angina pectoris. It reduces heart rate and blood pressure by blocking beta-adrenergic receptors, with cardioselective effects at therapeutic doses. The drug has a long duration of action (24+ hours) and undergoes minimal hepatic metabolism, relying primarily on renal excretion.
$0.004BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Medicare spending, indicating a mature, declining franchise with reduced team investment priorities.
Mechanism of Action
CLINICAL PHARMACOLOGY Atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. This preferential effect is not absolute, however, and at higher doses, atenolol inhibits beta 2…
Worked on TENORMIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.